Abstract
RESPIRE 1, an international Phase III trial, aimed to evaluate if Ciprofloxacin DPI as long-term, intermittent therapy in bronchiectasis patients (non-CF etiology) with ≥2 exacerbations (prior 12 months) and respiratory pathogens reduces exacerbations and improves quality-of-life (QoL). We investigated concomitant treatment use at baseline in different countries.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
